CN106458921B - 作为甲酰肽受体调节剂的咪唑衍生物 - Google Patents

作为甲酰肽受体调节剂的咪唑衍生物 Download PDF

Info

Publication number
CN106458921B
CN106458921B CN201580026983.9A CN201580026983A CN106458921B CN 106458921 B CN106458921 B CN 106458921B CN 201580026983 A CN201580026983 A CN 201580026983A CN 106458921 B CN106458921 B CN 106458921B
Authority
CN
China
Prior art keywords
unsubstituted
alkyl
compound
halogen
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580026983.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN106458921A (zh
Inventor
R·L·比尔德
T·T·杜昂
M·E·贾斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN106458921A publication Critical patent/CN106458921A/zh
Application granted granted Critical
Publication of CN106458921B publication Critical patent/CN106458921B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580026983.9A 2014-05-21 2015-05-21 作为甲酰肽受体调节剂的咪唑衍生物 Active CN106458921B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462001188P 2014-05-21 2014-05-21
US62/001,188 2014-05-21
PCT/US2015/032069 WO2015179707A1 (en) 2014-05-21 2015-05-21 Imidazole derivatives as formyl peptide receptor modulators

Publications (2)

Publication Number Publication Date
CN106458921A CN106458921A (zh) 2017-02-22
CN106458921B true CN106458921B (zh) 2020-03-24

Family

ID=53276329

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580026983.9A Active CN106458921B (zh) 2014-05-21 2015-05-21 作为甲酰肽受体调节剂的咪唑衍生物

Country Status (12)

Country Link
US (2) US10301269B2 (enExample)
EP (1) EP3145916B1 (enExample)
JP (1) JP6660889B2 (enExample)
KR (1) KR20170005121A (enExample)
CN (1) CN106458921B (enExample)
AU (2) AU2015264021B2 (enExample)
BR (1) BR112016027133A8 (enExample)
CA (1) CA2948876A1 (enExample)
DK (1) DK3145916T3 (enExample)
ES (1) ES2788700T3 (enExample)
RU (1) RU2748652C2 (enExample)
WO (1) WO2015179707A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
SI2770989T1 (sl) 2011-10-26 2018-12-31 Allergan, Inc. Aminokisline, substituirane z amidnimi derivati N-sečnine, kot so modulatorji receptorja za formil peptidnemu receptorju podobni receptor(FPRL-1)
KR20210024691A (ko) * 2013-03-06 2021-03-05 알러간, 인코포레이티드 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도
EP3071548B1 (en) 2013-11-21 2017-11-08 Allergan, Inc. Phenylcarbamate derivatives as formyl peptide receptor modulators
ES2788700T3 (es) 2014-05-21 2020-10-22 Allergan Inc Derivados de imidazol como moduladores del receptor de péptido formilado
EP3442950A1 (en) 2016-04-12 2019-02-20 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047899A2 (en) * 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
CN101801962A (zh) * 2007-07-09 2010-08-11 阿斯利康(瑞典)有限公司 用于治疗增殖疾病的三取代嘧啶衍生物
WO2013062947A1 (en) * 2011-10-26 2013-05-02 Allergan, Inc. Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
WO2013070600A1 (en) * 2011-11-10 2013-05-16 Allergan, Inc. Aryl urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
WO2013071203A1 (en) * 2011-11-10 2013-05-16 Allergan, Inc. 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (fprl-1) receptor modulators
WO2013122953A1 (en) * 2012-02-16 2013-08-22 Allergan, Inc. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
DK1723128T3 (da) 2004-01-06 2013-02-18 Novo Nordisk As Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
WO2007086584A1 (ja) * 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤
WO2008023159A1 (en) * 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
WO2009000748A1 (en) 2007-06-27 2008-12-31 Solvay Fluor Gmbh Preparation of compounds with a perfluoroalkylsulfonyl group
CN101998680B (zh) * 2009-08-24 2016-01-13 中兴通讯股份有限公司 帧序列号的发送方法及节点b和服务无线网络控制器
AU2011336973A1 (en) 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
US8580817B2 (en) 2011-02-11 2013-11-12 Allergan, Inc. 1-(1-OXO-1,2,3,4-tetrahydroisoquinolin-7-YL)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
WO2013009543A1 (en) 2011-07-11 2013-01-17 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
AU2013249474A1 (en) 2012-04-16 2014-11-06 Allergan, Inc. (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
KR20210024691A (ko) 2013-03-06 2021-03-05 알러간, 인코포레이티드 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도
MX364916B (es) 2013-03-06 2019-05-13 Allergan Inc Uso de agonistas de receptor de péptido formilo 2 para tratar enfermadades inflamatorias oculares.
JP6653253B2 (ja) 2013-07-16 2020-02-26 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体
EP3071548B1 (en) 2013-11-21 2017-11-08 Allergan, Inc. Phenylcarbamate derivatives as formyl peptide receptor modulators
WO2015116574A1 (en) 2014-01-29 2015-08-06 Allergan, Inc. Urea hydantoin derivatives as formyl peptide modulators
US9920013B2 (en) 2014-01-29 2018-03-20 Allergan, Inc. 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
ES2788700T3 (es) 2014-05-21 2020-10-22 Allergan Inc Derivados de imidazol como moduladores del receptor de péptido formilado
CA3017967A1 (en) 2016-03-28 2017-10-05 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
EP3442950A1 (en) 2016-04-12 2019-02-20 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047899A2 (en) * 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
CN101801962A (zh) * 2007-07-09 2010-08-11 阿斯利康(瑞典)有限公司 用于治疗增殖疾病的三取代嘧啶衍生物
WO2013062947A1 (en) * 2011-10-26 2013-05-02 Allergan, Inc. Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
WO2013070600A1 (en) * 2011-11-10 2013-05-16 Allergan, Inc. Aryl urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
WO2013071203A1 (en) * 2011-11-10 2013-05-16 Allergan, Inc. 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (fprl-1) receptor modulators
WO2013122953A1 (en) * 2012-02-16 2013-08-22 Allergan, Inc. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
RN：1378482-06-4，RN：1378391-54-8，RN：1378385-01-3;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20120614 *
RN：1378970-43-4;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20120615 *
RN：1379170-34-9;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20120617 *
RN：1423602-69-0;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20130314 *
RN：1424349-94-9;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20130315 *
RN：1428092-78-7;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20130411 *
RN：1477542-70-3;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20131120 *
RN：1479511-24-4，RN：1479406-85-3;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20131124 *
RN：1483807-63-1;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20131129 *
RN：1491331-55-5;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20131210 *
RN：1492584-16-3;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20131211 *
RN：1496192-08-5;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20131216 *
RN：1497615-40-3;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20131218 *
RN：1549726-72-8;ACS，STN Registry数据库;《ACS，STN Registry数据库》;20140219 *

Also Published As

Publication number Publication date
DK3145916T3 (da) 2020-05-11
US10301269B2 (en) 2019-05-28
BR112016027133A2 (pt) 2017-08-15
JP6660889B2 (ja) 2020-03-11
EP3145916A1 (en) 2017-03-29
AU2015264021B2 (en) 2020-02-27
RU2016145596A3 (enExample) 2018-11-19
JP2017520528A (ja) 2017-07-27
US20200115346A1 (en) 2020-04-16
CN106458921A (zh) 2017-02-22
RU2016145596A (ru) 2018-06-21
WO2015179707A1 (en) 2015-11-26
AU2020203420B2 (en) 2021-12-16
ES2788700T3 (es) 2020-10-22
KR20170005121A (ko) 2017-01-11
CA2948876A1 (en) 2015-11-26
EP3145916B1 (en) 2020-02-12
US20170096401A1 (en) 2017-04-06
BR112016027133A8 (pt) 2021-06-29
AU2015264021A1 (en) 2016-12-01
RU2748652C2 (ru) 2021-05-28
US10800744B2 (en) 2020-10-13
AU2020203420A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
CN106458921B (zh) 作为甲酰肽受体调节剂的咪唑衍生物
RU2627271C2 (ru) Производные арилмочевины в качестве модуляторов n-формилпептидного-1 рецептора (fprl-1)
US9670150B2 (en) (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
JP6653253B2 (ja) ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体
AU2014352922B2 (en) Phenylcarbamate derivatives as formyl peptide receptor modulators
WO2015042071A1 (en) Diphenyl urea derivatives as formyl peptide receptor modulators
US9604934B2 (en) Urea hydantoin derivatives as formyl peptide modulators
US9868700B2 (en) Carbamoyl hydrazine derivatives as formyl peptide modulators
US9920013B2 (en) 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators
JP2019517997A (ja) Ｎ−ホルミルペプチド受容体モジュレーターとしてのフェニル尿素誘導体
HK40008283A (en) Phenyl urea derivatives as n-formyl peptide receptor modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant